Wells Fargo & Company Sonoma Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.14 - $0.26 $12 - $23	-89 Reduced 72.95%	33 $0
Q1 2024 May 10, 2024	BUY	$0.13 - $0.23 $2 - $3	17 Added 16.19%	122 $0
Q4 2023 Feb 09, 2024	BUY	$0.14 - $0.77 $9 - $51	67 Added 176.32%	105 $0
Q3 2023 Nov 13, 2023	BUY	$0.76 - $1.16 $3 - $5	5 Added 15.15%	38 $0
Q2 2023 Aug 15, 2023	BUY	$0.92 - $1.4 $11 - $16	12 Added 57.14%	33 $0
Q2 2022 Aug 12, 2022	BUY	$2.65 - $4.12 $5 - $8	2 Added 10.53%	21 $0
Q1 2022 May 16, 2022	BUY	$2.65 - $4.84 $5 - $9	2 Added 11.76%	19 $0
Q4 2021 Feb 14, 2022	BUY	$4.32 - $6.27 $17 - $25	4 Added 30.77%	17 $0
Q1 2021 May 13, 2021	BUY	$6.81 - $9.64 $6 - $9	1 Added 8.33%	13 $0
Q1 2020 May 14, 2020	BUY	$3.71 - $6.05 $44 - $72	12 New	12 $0

2.27K

Ticker SNOA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 3,100,940
Market Cap $8.84M
Description
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.